The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Antitumor activity observed in a phase I drug–drug interaction study of cabozantinib (XL184) and rosiglitazone in patients (pts) with renal cell carcinoma (RCC) and differentiated thyroid cancer (DTC).
T. K. Choueiri
Consultant or Advisory Role - AVEO; Bayer; Eisai; Genentech; GlaxoSmithKline; Novartis; Onyx; Pfizer
S. K. Pal
No relevant relationships to disclose
M. E. Cabanillas
Research Funding - Exelixis
D. A. Ramies
Employment or Leadership Position - Exelixis
Stock Ownership - Exelixis
L. Tseng
Employment or Leadership Position - Exelixis
Stock Ownership - Exelixis
J. S. Holland
Employment or Leadership Position - Exelixis
Stock Ownership - Exelixis
S. Morrissey
No relevant relationships to disclose
J. P. Dutcher
No relevant relationships to disclose